menu search

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s

– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab ta...

June 3, 2023, 8:00 pm

Cogent biosciences announces positive lead-in data from ongoing phase 3 peak trial evaluating bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors (gist)

– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST ...

June 3, 2023, 6:15 pm

Replimune presents rp1 data from the ignyte anti-pd1 failed melanoma cohort and rp2 data in uveal melanoma at the 2023 american society of clinical oncology (asco) annual meeting

Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses...

June 3, 2023, 6:15 pm

Bitmex co-founder lists reasons for bitcoin’s mild reaction to us banking crisis

BitMEX co-founder Arthur Hayes published a blog post titled “patience is Beautiful,” shedding light...

June 3, 2023, 6:14 pm

Usd/cad weekly outlook

USD/CAD fell sharply last week but overall outlook is unchanged. Initial bias remains neutral this week first. Price actions from 1.3976 are seen as a...

June 3, 2023, 3:05 pm

Eur/jpy weekly outlook

EUR/JPY failed to break through 151.60 resistance last week, and retreated. Initial bias remains neutral this week first. On the downside, below 148.5...

June 3, 2023, 2:55 pm

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of ...

June 3, 2023, 1:00 pm

Allogene therapeutics presents updated allo-501/501a phase 1 data in large b cell lymphoma at the american society of clinical oncology (asco) annual meeting

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Simila...

June 3, 2023, 1:00 pm

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of ...

June 3, 2023, 1:00 pm

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of ...

June 3, 2023, 1:00 pm

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of ...

June 3, 2023, 1:00 pm

Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of ...

June 3, 2023, 1:00 pm


Search within

Pages Search Results: